BMS secures FDA accelerated approval for Zenbexus in multiple myeloma

Zenbexus is said to be the first CELMoD therapy approved by the FDA for multiple myeloma treatment. Credit: Bristol-Myers Squibb / Business Wire.



  • BMS FDA Zenbexus